A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This single arm study will assess the efficacy and safety of quarterly intravenous Bonviva in women with post-menopausal osteoporosis. All patients will receive Bonviva 3mg i.v. every 3 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100 individuals.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
up to 80 Years (Child, Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
post-menopausal women with osteoporosis;
<=80 years of age;
naive to oral bisphosphonates, or have discontinued daily and/or weekly bisphosphonate treatment for >1 year.
metabolic bone disease other than post-menopausal osteoporosis;
treatment with other drugs affecting bone metabolism within last 6 months;
previous or current malignant disease (except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer).